Estrogen regulates the growth of a proportion of breast cancers through an estrogen receptor (ER) mediated mechanism. Loss of the ER is associated with a loss of estrogen (E2) regulation and a resistance to antiestrogen therapy. Since no effective therapeutic intervention is available to treat the ER negative patient new initiatives are essential to develop a new treatment strategy. One approach would be either to reactivate the ER gene or to develop a targeted """"""""gene therapy"""""""" to re-introduce constitutive production of ER. Our strategic goal is to determine whether the ER could reassert control over the growth of receptor negative breast cancer cells. We are the first group to transfect a breast cancer cell line (MDA-MB-231) with sense and antisense cDNA for both mutant (valine replacing glycine at AA400) and wild type ER. The 8 different cloned cell lines, that constitutively produce ER, were selected by polycistronic production of mRNA for aminoglycoside phosphotransferase which confers resistance in media containing G418. The ER is functional and can activate vit ERETK-CAT however the wild type transfectant is approximately 20 times more sensitive that the mutant transfectant. The ER levels, determined by whole cell uptake of (3 HE-2) are in the range (300-520 fmole/mg protein) of MCF-7 breast cancer cells (500 fmole/mg protein). Interestingly enough E2 inhibits growth of all the transfectants in a concentration related manner. The inhibition is blocked by the pure antiestrogen ICI 164,384. In contrast an analog of the triphenylethylene 4 hydroxytamoxifen (40HT) is a partial agonist/antagonist in the wild type transfectants but an estrogen agonist in the mutant transfectants.
The aims of the proposal are to characterize the cell cycle kinetics and cell biology of our current and additional transfectants and to determine the effect of increasing the receptor number in other breast cancer cell lines. Colon cancer cell line HT-29 will be transfected with ER to broaden our finding to other target organs not previously regulated by estrogen. Additionally we have been intrigued by the alteration in pharmacology of 40HT with the mutant receptor; we will establish a model for antiestrogen drug resistance based on alterations in the ligand, receptor and hormone response element. There is evidence that the inhibitory effect of E2 on ER transfected receptor negative cells is universal so these studies will provide the first solid mechanistic evidence to pursue a new therapeutic approach to breast cancer. In the future the pharmacologist may not only alter the ligand requirements but also be able to target or reactive quiescent receptors as a new general therapeutic strategy for cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA056143-02
Application #
3200656
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1992-09-10
Project End
1994-04-12
Budget Start
1993-08-01
Budget End
1994-04-12
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Bentrem, D; Dardes, R; Liu, H et al. (2001) Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 142:838-46
Jordan, V C (2001) Selective estrogen receptor modulation: a personal perspective. Cancer Res 61:5683-7
MacGregor Schafer, J; Liu, H; Levenson, A S et al. (2001) Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 78:41-50
MacGregor Schafer, J; Liu, H; Bentrem, D J et al. (2000) Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 60:5097-105
Schafer, J M; Lee, E S; O'Regan, R M et al. (2000) Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 6:4373-80
Schafer, J I; Liu, H; Tonetti, D A et al. (1999) The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res 59:4308-13
Levenson, A S; Svoboda, K M; Kwaan, H C et al. (1998) Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer Lett 125:215-20
Levenson, A S; Jordan, V C (1998) The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58:1872-5
MacGregor, J I; Jordan, V C (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50:151-96
Levenson, A S; Kwaan, H C; Svoboda, K M et al. (1998) Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 78:88-95

Showing the most recent 10 out of 25 publications